



## ANEMIA PROFILE IN PATIENTS WITH CONGESTIVE HEART FAILURE AND THEIR 6 MONTHS FOLLOW UP STUDY IN A TERTIARY CARE CENTRE, KERALA

### Cardiology

**Dr Praveen Velappan\***

\*Corresponding Author

**Dr Baiju Rajan**

**Dr Vidyasagar Karanam**

### KEYWORDS

#### INTRODUCTION

Heart failure is an enormous medical and societal burden and a leading cause of hospitalization. The overall prevalence of HF is thought to be increasing, in part because current therapies for cardiac disorders (e.g., myocardial infarction, valvular heart disease, arrhythmias) are allowing patients to survive longer. Worldwide, HF affects almost 23 million people. Estimated prevalence of symptomatic HF in the general European population is similar to that in the United States and ranges from 0.4% to 2% (1). The current estimates about incidence of HF in India vary widely from 1.3 to 23 million as reported by Trivandrum Heart Failure Registry (2).

Anaemia and Renal failure seem to be major risk factors recognized in the pathophysiology and progression of Congestive Heart Failure (CHF) with an adverse outcome. The cardio renal anaemia syndrome (CRAS) represents a pathological triangle in which the primary failing organ is the heart or the kidney and the dysfunction of one organ leads to dysfunction of the other(3)(4). The presence of anemia increases morbidity and mortality in patients with heart failure. It seems that there is an impaired mechanism operating between congestive heart failure, chronic kidney disease (CKD), and anemia, where each might cause or worsen the other. Anaemia is independently associated with increased mortality and hospitalizations in patients with both Heart Failure with reduced Ejection Fraction (HFrEF) and HF with preserved ejection fraction. Therefore, correction of anaemia would be a major part of this vicious circle in the reduction of the severity of the heart failure. This could be explained by the fact that a significant feature of congestive heart failure is impaired energy metabolism and therefore the failing heart is an energy-starved heart. Oxygen delivery through haemoglobin (Hb) is essential for energy production and improvement of Hb levels could also improve energy production in cardiomyocytes. (5)

There is a paucity of data available about the prevalence and characteristics of anemia in CHF patients in India. Previous Indian studies have found prevalence of anemia to vary considerably from 4%–55 % (6). However, not much is known about the prevalence, predictors, and prognosis of Iron Deficiency (ID) in patients with Congestive Heart Failure (CHF). ID is common in patients with heart failure, relates to disease severity, and is a strong and independent predictor of outcome (7).

Different studies showed reduction in readmission with HF after giving intravenous iron therapy, but so far there have been no conclusive mortality data(8) As such, there are still unclear aspects regarding the clinical implications of anemia in heart failure. The present study was designed to know the prevalence of this important comorbidity and that of underlying nutritional deficiencies (Serum Iron, Vitamin B12 and Folate) in patients of CHF and their follow up for 6 months.

#### AIMS OF THE STUDY

- To evaluate Anemia profile in patients with Congestive Heart Failure.
- To evaluate clinical and laboratory profile of anemic and non anemic group
- To evaluate Readmission rate and mortality in anemic and non anemic group of patients during 6 months follow-up

#### MATERIALS AND METHODS

##### Study Setting

Government TD Medical College, Alappuzha is a tertiary level multispecialty Hospital in the coastal South India. Cardiac care is available 24 hours, 7 days a week in Department of Cardiology. Patients coming to the institute either in OPD or in wards with CHF will be subjected to thorough clinical evaluation and complete laboratory evaluation for anemia profile and follow up of these patients were done by regular OPD visits and through telephonic conversation over a period of 6 months.

##### Study Design

Descriptive Observational Study

##### B) Study Period

The study was conducted during 6 months period after ethical committee clearance and follow up done for 6 months.

##### Study Population

Sample size: Considering the prevalence of anemia in CHF patient as 37% (10-49%) from previous reference studies and keeping  $\alpha = 0.05$ , for power of 90% a minimum sample size of 171 is assigned. In this study 200 patients were taken as sample size.

##### Inclusion Criteria

All consecutive patients having clinical criteria for heart failure (according to the Framingham criteria), who were 18 years or older in age and were in New York Heart Association (NYHA) functional class II-IV of more than three months duration at the time of enrolment were included in this study.

#### Diagnostic Criteria For Heart Failure (HF) In Population-based Studies (Framingham Criteria)

##### Major Criteria

- Paroxysmal nocturnal dyspnea or orthopnea
- Neck vein distension
- Rales
- Cardiomegaly
- Acute pulmonary edema
- S3 gallop
- Increased venous pressure >16 cm H<sub>2</sub>O
- Hepatojugular reflux

##### Minor Criteria

- Ankle edema
- Night cough
- Dyspnea on exertion
- Hepatomegaly
- Pleural effusion
- Vital capacity decreased One-third from maximal capacity
- Tachycardia (rate >120/min)

##### Major or Minor Criteria

1. Weight loss >4.5 kg in 5 days in response to treatment  
The diagnosis of HF using the Framingham criteria requires the simultaneous presence of at least 2 major criteria or 1 major criterion in conjunction with 2 minor criteria. Minor criteria are acceptable only if they cannot be attributed to another medical condition (e.g.,

Pulmonary Hypertension, Chronic Lung Disease, Cirrhosis, Ascites, Nephrotic Syndrome). [18]

**Exclusion Criteria**

Exclusion criteria are:

1. Acute coronary syndrome with heart failure.
2. Severe comorbidities like Chronic Kidney Disease, Chronic Lung Disease, Chronic Liver Disease, Nephrotic Syndrome.
3. Complex Cyanotic Congenital Heart Diseases.
4. Known malignant, haematological or other active neoplasia.
5. Immunosuppressive therapy, chemotherapy or radiotherapy within 3 months prior to enrolment.
6. Pregnant women

**METHODS**

All consecutive patients having clinical criteria for heart failure (according to the Framingham criteria), who were 18 years or older in age and were in NYHA functional class II- IV for more than 3 month duration at the time of enrolment were included in this study.

**BASELINE CLINICAL AND LABORATORY ASSESSMENT**

**History And Clinical Examination**

In all enrolled patients satisfying the inclusion criteria, a detailed history was taken and complete physical examination was conducted by the investigator.

At time of admission, detailed history with special emphasis on time of onset and duration of heart failure, drug history, past history of Coronary Artery Disease (CAD), Type 2 Diabetes mellitus (T2DM), Hypertension (HTN), Bleeding disorder, Chronic Kidney Disease (CKD), Family history of CAD was taken.

Upon recruitment, all the patients underwent the Baseline clinical evaluation and following laboratory evaluation:

1. Haemoglobin concentration
2. Haematocrit
3. Mean corpuscular volume
4. Mean corpuscular haemoglobin concentration
5. Red cell distribution width
6. Serum iron concentration
7. Serum transferrin saturation
8. Serum ferritin saturation
9. Total iron binding capacity
10. Serum vitamin B12 level
11. Serum folate level

**Definition of Anemia, iron, Vit B12 and folate deficiency**

1. Haemoglobin <13 gm/dl (males) and < 12 gm/dl (females) - Anemia (WHO criteria)
2. Serum ferritin < 100 ng/ml- ID
3. Serum ferritin 100–300 ng/ml with transferrin saturation <20%- ID
4. Serum Vit B12 <200 pg/ml- Vitamin B12 deficiency
5. Serum folate <4 ng/ml – Folate deficiency

Outcomes measurement: The study population was categorized into two groups

- A. Anemic Group
- B. Non-anemic Group.

Each group was further sub categorized as having iron, B12 or folate deficiency or combined iron and B12/folate deficiency according to the definitions.

**Follow Up:**

All patients included in the study were followed upto 6 months on OPD or telephonic basis. During follow up evaluation, patients were evaluated on symptoms of heart failure, readmission rates and their mortality.

**Statistical Methods**

Statistical testing was conducted with the statistical package for the social science system version SPSS 22.0. Data was presented as Mean, Standard deviation (SD), frequencies and percentages. All variables were expressed as mean ± standard deviation. The Chi-square test was used to analyse categorical variables. Student's t test and analysis of variance was used for continuous variables.

**ETHICAL CONSIDERATION**

Study was conducted after getting approval from Institutional Research

Committee. A written informed consent was taken from all patients / relatives participating in the study.

**RESULTS:**


200 patients admitted to hospital with clinical diagnosis of HF were studied, out of which 132 (66%) were males and 68 (34%) were females. Mean age of the study subjects was 59.12 years, mean EF of 38.5%.

**BASELINE CHARACTERISTICS OF STUDY POPULATION:**

**Table No : 1**

TOTAL PATIENTS	200
MALES	132(66%)
FEMALES	68(34%)
MEAN AGE	59.12
MALES	59
FEMALES	59.6
AGE GROUP	
<50 YRS	56(28%)
50-70 YRS	112(56%)
>70 YRS	32(16%)
NYHA FC- MEAN	
NYHA FC I,II	64(32%)
NYHA FC III	90(45%)
NYHA FC IV	46(23%)
DM	88(44%)
HYPERTENSION	72(36%)
ISCHEMIC HEART DISEASE	136(68%)
NON ISCHEMIC HEART DISEASE	64(32%)
EJECTION FRACTION -MEAN	
<30%	42(21%)
31-40%	86(43%)
40-55%	34(17%)
>55 %	38(19%)
ATRIAL FIBRILLATION	38(19%)

Diabetes mellitus was seen in 88 (44%) patients. Hypertension was seen in 72 (32%) patients. Ischemic cardiac disease was the predominant cause of heart failure constituting 68% (136) of patients and non-ischemic cause of heart failure seen in 32% (64) patients.



**Table No: 2**


	ANEMIC – 98 (46%)	NON ANEMIC -102(54%)
IRON DEFICIENCY	54(27%)	30 (15%)
S.VIT B12 DEF	22(11%)	6(3%)
S. FOLATE DEF	12(6%)	2(1%)
COMBINED DEF	10(5%)	4(2%)

Overall, 46 % patients had anemia. In the anemic group, ID was found in 27% patients, 11% patients had Vitamin B12 deficiency and 12% patients had Folate deficiency. In the non-anemic group, ID was present in 15%, B12 deficiency seen in 3% and Folate deficiency seen in 1% of patients. Out of 200 patients, Vitamin B12 deficiency is seen in 14 % and Folate deficiency is seen in 7% of patients.

**Table No: 3**

	Males (132)	Females (68)	Total (200)
Absolute ID	36(27.27%)	24 (35.2%)	60(30%)
With anemia	26	14	40(20%)
Without anemia	10	10	20(10%)

Functional ID	12 (9.9%)	12(17.6%)	24(12%)
With anemia	6	8	14(7%)
Without anemia	6	4	10 (5%)
Absolute or functional ID	48 (36.6%)	36(52.9%)	84(42%)
With anemia	32	22	54(27%)
Without anemia	16	14	30(16%)



Absolute ID (serum ferritin < 100 mg/L) was present in 60 (30%) patients. Absolute ID with anemia (Hb < 13 g% for male and <12 g% for females) was present in 40 (20%) patients. Functional ID (serum ferritin 100–300 mg/L with TSAT < 20%) was present in 24 (12%) patients and functional ID with anemia was present in 14 (7%) patients. Thus ID (either absolute or functional) was found in 84(42%) patients and ID with anemia was present in 54 (27%) patients.




Table 5:

Parameter	Group I (Anemic) N= 98	Group II (Non – Anemic) N= 102	P Value
Index hospitalization			
Duration of hospitalization over 7 days	28(28.5%)	31(30.3%)	0.89
In hospital mortality	5(5.1%)	7(6.8%)	0.82

Long duration of hospitalisation for more than 7 days was seen in 28(28.5%) out of 98 patients in anemic group and 31(30.3%) out of 102 patients in anemic group . In hospital mortality at the index admission was seen in 5(5.1%) and 7(6.8%)patients in anemic and non anemic groups respectively .The difference in long duration of hospitalization and mortality in anemic and non anemic groups is statistically not significant.

Table 6:

Data During 6 Months Follow Up	GROUP I (Anemia) 93	GROUP II (No anemia) 95	P VALUE
Re admissions	28(30.1%)	16(16.8%)	0.04
Death	23(23.4%)	14(13.7%)	0.11

28(30.1%) out of 93 patients in anemic group and 16(16.8%)out of 95 patients in non anemic group were admitted again in hospital within a span of 6 months after index hospitalization and this value is statistically significant . Overall mortality is seen in 23(23.4%) patients in anemic group and 14(13.7%) patients in non anemic group which is not statistically significant.

Table 7 : Predictive Factors For Long Duarition Of Hospitalization

50	International Journal of Scientific Research
----	--

And Their Univariate And Multi Variate Analysis

Parameter	Univariate Analysis		Multivariate Analysis	
	Relative Risk(CI)	P Value	Relative Risk	P Value
INFECTION	1.94 (1.0023-2.150)	0.002	1.342 (0.886-2.389)	0.07
ARRYTHMIA	1.03 (1.0027-4.218)	0.003	1.374 (1.0023-2.110)	0.08
HEART RATE	2.95 (1.6810-4.3129)	0.01	2.12 (2.039-4.276)	0.93

Long duration of hospitalization predictive factors are infection ,arrythmia and heart rate as seen in univariate analysis but none of the them were statistically significant in multivariate analysis.

Table 8 : Predictive Factors For In Hospital Mortality And Their Univariate And Multi Variate Analysis

Parameter	Univariate Analysis		Multivariate Analysis	
	Relative Risk	P Value	Relative Risk	P Value
ANEMIA	1.9 (1.238-6.893)	0.01	0.9 (0.780-1.865)	0.10
INFECTION	0.98 (0.885-1.590)	0.02	0.45 (0.286-1.438)	0.67
HEART RATE	1.02 (0.843-1.86)	0.001	0.79 (0.561-3.123)	0.003
ARRYTHMIA	3.98 (2.12-3.964)	0.005	2.1 (1.974-2.967)	0.43
CRF	4.92 (1.039-6.769)	0.04	3.16 (1.21- 5.956)	0.64

Predictive factors for in hospital mortality are anemia,infection,heart rate ,arrythmia and renal failure .In multivariate analysis ,except for heart rate other factors are not significant as individual components predicting the in hospital mortality

Predictive Factors For Mortality After 6 Months And Their Univariate And Multi Variate Analysis

Parameter	Univariate Analysis		Multivariate Analysis	
	Relative Risk	P Value	Relative Risk	P Value
ANEMIA	0.42(0.218-0.867)	0.002	0.8(0.634-3.128)	0.67
ARRYTHMIA	2.76(0.659-3.970)	0.001	2.06(1.96-4.241)	0.57

Predictive factors for mortality in 6 months follow up are presence of anaemia and arrythmia .These factors are not significant in multivariate analysis

DISCUSSION

Anemia is commonly present in CHF patients. ID in CHF is associated with reduced iron stores in the bone marrow and the heart. ID is an independent risk factor for severity , worsening of the CHF & mortality.

Epidemiology Of Anemia In CHF

A recent meta-analysis of 153,180 patients with CHF, reported in 34 published studies from 2001 to 2007, estimated the prevalence of anemia to be 37.2% (10– 49%). Estimates of the prevalence of anemia in patients with CHF and low ejection fraction range widely from 4% to 61% (median 18%)(9,10).

In our study, we found the prevalence of ID being 42% which is correlated with the prevalence in STAMINA-HFP (Study of Anemia in a Heart Failure Population) Registry which estimated a prevalence of 34% (10). But prevalence of anemia is less compared to Arora et al study which was done in 275 patients and showed a prevalence of 76.7%(6).

Iron Deficiency, Vitamin B12 Deficiency And Folate Deficiency

200 patients were enrolled in our study and complete evaluation of anemia was done. Our study found 46% prevalence of anemia as defined by the WHO criterion (Hb <13 gm/dL in males and < 12 gm/dL in females). Iron Deficiency was found in 42% patients in our study. The prevalence of ID was similar to that described by McDonagh et al (11), but it was lower than that described in a recent study by Sharma et al (12). This study had included 150 CHF patients and Iron Deficiency was present in 76% of the patients (Table 3). Our values are comparable to study done by Vander al Wal(13) which showed Iron Deficiency ,vitamin B 12 deficiency , Folate deficiency of 58%, 4%,

5% respectively.

In comparison to the study by Sharma et al, we also measured the prevalence of vitamin B12 and Folate deficiency in our patients.

Overall, 14% patients had vitamin B12 deficiency (defined as serum vitamin B12 <200 pg/ml) and 7 % patients had Folate Deficiency (i.e. serum folate <4 ng/ml). Combined deficiency is seen in 7% of patients.

### MORTALITY AND MORBIDITY DURING 6 MONTHS FOLLOW UP

Number of patients requiring long duration of hospitalization and mortality at index hospitalization were evaluated in our study. There is no significant difference between anaemic and non anaemic groups of patients regarding mortality at index hospitalization. But in other studies like Ye et al. (14) evaluated the overall all-cause mortality in 3,279 patients and reported a significant (p: 0.01) increase in the mortality-related events in HF patients with anaemia as compared to patients without anaemia. This relationship between anaemia and mortality was proportional to the severity of the anaemia i.e., the more severe the anaemia, the higher the mortality rates. Jin et al. (15) reported higher mortality related outcomes for the anemic group (14.6%) as compared to the non-anemic group (8.7%) in a Chinese cohort of 1,604 patients. our study results are comparable to Parvanescu et al study which included 134 patients (16).

Predictive factors for long duration of hospital stay (infection ,arrhythmia and heart rate) are analysed in the study but none of the them were significant in multivariate analysis.

Rehospitalisation and mortality during 6 months follow up were also evaluated in this study. Rehospitalisation rate was significantly higher in anemic group compared to non anemic group (p value 0.004) and these findings are similar to Felker et al study (17).

Although anemia is a contributor factor in mortality in CHF patients but our study didn't show any significant difference between anemic and non anemic group . Predictive factors for in hospital mortality are anemia ,infection, heart rate ,arrhythmia and renal failure .In multivariate analysis ,except for heart rate other factors are not significant as individual components predicting the in hospital mortality. Patients with high heart rate are found to be at increased risk of death.

In IRON HF study, intravenous iron treatment in patients with iron deficiency anemia and heart failure resulted in improvement in the quality of life, exercise tolerance and NYHA functional class (8). In addition, the CONFIRM-HF study showed a significant reduction in readmissions due to worsening of heart failure, with an insignificant reduction in mortality (18).

### LIMITATIONS OF THE STUDY

1. This study is a prospective observational study conducted at a tertiary care centre in South Kerala. It is difficult to generalize the findings for our entire nation with different cultures and food habits, necessitating multicenter large-scale studies.
2. No controls were taken to compare Iron Deficiency in subjects with or without Heart Failure.
3. Heart failure with reduced and preserved ejection fraction are included in the study. There is no separate analysis for HFpEF and HFrEF.
4. Effect of iron supplementation on improvement of NYHA class was not analysed in this study.

### CONCLUSION:

Our study highlights the underestimated Iron Deficiency in Heart Failure patients and importance of doing complete iron profile in heart failure patients.

Our study shows that anemia is one of the contributors for mortality in CHF patients and there is no significant difference between anemic and non anemic groups .This study suggests there is need to do large-scale studies for better evaluation of this easily treatable condition.

### REFERENCES:

1. Heart Disease and Stroke Statistics—2016 Update | Circulation [Internet]. [cited 2021 Dec 19]. Available from: <https://www.ahajournals.org/doi/10.1161/cir.00000000000000350>
2. Hari Krishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG,

- et al. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. *Eur J Heart Fail.* 2015 Aug;17(8):794–800.
3. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. *J Am Coll Cardiol.* 1992 Jul 1;20(1):248–54.
4. Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. *Clin Nephrol.* 2003 Jul;60 Suppl 1:S93–102.
5. The Failing Heart — An Engine Out of Fuel | NEJM [Internet]. [cited 2021 Dec 19]. Available from: <https://www.nejm.org/doi/10.1056/NEJMra063052>
6. Arora H, Sawhney JPS, Mehta A, Mohanty A. Anemia profile in patients with congestive heart failure a hospital based observational study. *Indian Heart J.* 2018 Dec;70 Suppl 3:S101–4.
7. Adams KF, Piña IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, et al. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. *Am Heart J.* 2009 Dec;158(6):965–71.
8. Beck-da-Silva L, Piarli D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. *Int J Cardiol.* 2013 Oct 9;168(4):3439–42.
9. Gehi A, Ix J, Shlipak M, Pipkin SS, Whoolley MA. Relation of Anemia to Low Heart Rate Variability in Patients With Coronary Heart Disease (from the Heart and Soul Study). *Am J Cardiol.* 2005 Jun;95(12):1474–7.
10. Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis | Journal of the American College of Cardiology [Internet]. [cited 2021 Dec 19]. Available from: <https://www.jacc.org/doi/abs/10.1016/j.jacc.2008.04.061>
11. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? *Eur J Heart Fail.* 2015 Mar;17(3):248–62.
12. Sharma SK, Agarwal SK, Bhargava K, Sharma M, Chopra K, Arumugam G. Prevalence and spectrum of iron deficiency in heart failure patients in south Rajasthan. *Indian Heart J.* 2016;68(4):493–7.
13. van der Wal HH, Comin-Colet J, Klip IT, Enjuanes C, Grote Beverborg N, Voors AA, et al. Vitamin B12 and folate deficiency in chronic heart failure. *Heart Br Card Soc.* 2015 Feb;101(4):302–10.
14. Xia H, Shen H, Cha W, Lu Q. The Prognostic Significance of Anemia in Patients With Heart Failure: A Meta-Analysis of Studies From the Last Decade. *Front Cardiovasc Med [Internet].* 2021 [cited 2022 Aug 8];8. Available from: <https://www.frontiersin.org/articles/10.3389/fcvm.2021.632318>
15. Jin X, Cao J, Zhou J, Wang Y, Han X, Song Y, et al. Outcomes of patients with anemia and renal dysfunction in hospitalized heart failure with preserved ejection fraction (from the CN-HF registry). *Int J Cardiol Heart Vasc.* 2019 Aug 31;25:100415.
16. Parvanescu T, Buz B, Bordejevic DA, Caruntu F, Trofenciu M, Tomescu MC, et al. The Prognostic Role of Anemia in Heart Failure Patients. *Rev Chim.* 2020 Feb 7;71(1):185–91.
17. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiadu M, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. *Am J Cardiol.* 2003 Sep 1;92(5):625–8.
18. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. *Eur Heart J.* 2015 Mar 14;36(11):657–68.
19. Iron deficiency in the elderly population, revisited in the hepcidin era [Internet]. [cited 2021 Dec 19]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006029/>
20. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonnini L, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. *J Card Fail.* 2005 Mar;11(2):91–8.
21. Kansagara D, Dyer E, Englander H, Freeman M, Kagen D. Treatment of Anemia in Patients with Heart Disease: A Systematic Review [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011 [cited 2021 Dec 19]. (VA Evidence-based Synthesis Program Reports). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK83423/>
22. Silverberg DS, Wexler D, Blum M, Iaina A, Sheps D, Keren G, et al. Effects of Treatment with Epoetin Beta on Outcomes in Patients with Anaemia and Chronic Heart Failure. *Kidney Blood Press Res.* 2005;28(1):41–7.
23. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation.* 2017 Aug 8;136(6):e137–61.
24. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol.* 1993 Oct;22(4 Suppl A):6A–13A.